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Statin Use and Adverse Effects Among Adults >75 Years of Age:
Insights From the Patient and Provider Assessment of Lipid
Management (PALM) Registry
Michael G. Nanna, MD; Ann Marie Navar, MD, PhD; Tracy Y. Wang, MD, MHS, MSc; Xiaojuan Mi, PhD; Salim S. Virani, MD, PhD;
Michael J. Louie, MD, MPH, MSc; L. Veronica Lee, MD; Anne C. Goldberg, MD; Veronique L. Roger, MD, MPH; Jennifer Robinson, MD, MPH;
Eric D. Peterson, MD, MPH
Background-—Current statin use and symptoms among older adults in routine community practice have not been well
characterized since the release of the 2013 American College of Cardiology/American Heart Association guideline.
Methods and Results-—We compared statin use and dosing between adults >75 and ≤75 years old who were eligible for primary
or secondary prevention statin use without considering guideline-recommended age criteria. The patients were treated at 138 US
practices in the Patient and Provider Assessment of Lipid Management (PALM) registry in 2015. Patient surveys also evaluated
reported symptoms while taking statins. Multivariable logistic regression models examined the association between older age and
statin use and dosing. Among 6717 people enrolled, 1704 (25%) were >75 years old. For primary prevention, use of any statin or
high-dose statin did not vary by age group: any statin, 62.6% in those >75 years old versus 63.1% in those ≤75 years old (P=0.83);
high-dose statin, 10.2% versus 12.3% in the same groups (P=0.14). For secondary prevention, older patients were slightly less likely
to receive any statin (80.1% versus 84.2% [P=0.003]; adjusted odds ratio, 0.81; 95% conﬁdence interval, 0.66–1.01 [P=0.06]), but
were much less likely to receive a high-intensity statin (23.5% versus 36.2% [P<0.0001]; adjusted odds ratio, 0.54; 95% conﬁdence
interval, 0.45–0.65 [P=0.0001]). Among current statin users, older patients were slightly less likely to report any symptoms (41.3%
versus 46.6%; P=0.003) or myalgias (27.3% versus 33.3%; P<0.001).
Conclusions-—Overall use of statins was similar for primary prevention in those aged >75 years versus younger patients, yet older
patients were less likely to receive high-intensity statins for secondary prevention. Statins appear to be similarly tolerated in older
and younger adults. ( J Am Heart Assoc. 2018;7:e008546. DOI: 10.1161/JAHA.118.008546.)
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S tatins have proved beneﬁcial for the prevention ofcardiovascular disease in adults,1–3 but patients
>75 years have been underrepresented in randomized con-
trolled trials.4,5 In addition, concerns have been raised about
the adverse effects of statins and polypharmacy as a reason
not to treat older patients as aggressively as younger
patients.1,6 Although data are mixed for primary prevention
after the age of 75 years,7 studies in older patients with
atherosclerotic cardiovascular disease (ASCVD) suggest no
attenuation of beneﬁt. The 2013 American College of
Cardiology (ACC)/American Heart Association (AHA) Guide-
line on the Treatment of Blood Cholesterol to Reduce
Atherosclerotic Cardiovascular Risk in Adults acknowledges
the limitations of existing data on older individuals and
recommends individualizing the decision to initiate statins for
primary prevention in adults >75 years.1 For secondary
prevention, 3 trials found that high-intensity statin therapy
reduced cardiovascular events more than moderate-intensity
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statin therapy, but these trials enrolled few patients
>75 years and none >80 years8–10; however, there was
sufﬁcient evidence for moderate-intensity statin therapy in
secondary prevention patients of any age.11 The most recent
2016 US Preventive Services Task Force Recommendation
Statement on Statin Use for the Primary Prevention of
Cardiovascular Disease similarly avoids ﬁrm recommenda-
tions about statins for older adult patients (>75 years old), as
do the European Society of Cardiology/European Atheroscle-
rosis Society guidelines for the management of dyslipidemias
in patients >80 years old, with insufﬁcient evidence to make a
recommendation in this population.12,13
Our study was designed to evaluate patterns of statin use
and symptoms in older adults in contemporary community
practice. Using the Patient and Provider Assessment of Lipid
Management (PALM) registry, we determined whether adults
aged >75 were (1) less likely to be treated with a statin,
(2) less likely to be treated with a high-intensity statin, or
(3) more likely to have patient-reported symptoms than their
younger counterparts.
Methods
Data Description and Outcomes of Interest: PALM
Registry
The PALM registry is composed of 7736 patients with ASCVD
or at high risk for ASCVD from 138 cardiology, primary care,
and endocrinology practices nationwide.14 As described
previously,14 data were collected cross-sectionally at enroll-
ment and included patient demographic and socioeconomic
characteristics, comorbidities, medical history, core labora-
tory lipid panels, patient experiences, and beliefs about lipid-
lowering therapy from patient surveys and provider charac-
teristics. The data, analytic methods, and study materials will
not be made available to other researchers for purposes of
reproducing the results or replicating the procedure. All study
participants provided informed consent, and all sites obtained
institutional review board approval for participation.
For this analysis, patients ≤75 years were included if they
would have met a recommendation for high- or moderate-
intensity statin therapy under the most recent ACC/AHA
cholesterol guideline, and patients >75 years old were
included if they would have met an indication for statin
therapy independent of their chronologic age.1 Patients
qualiﬁed for high-intensity statin therapy for purposes of
secondary prevention if they had a history of clinical ASCVD.
Patients were classiﬁed as having ASCVD if they had prior
myocardial infarction, coronary artery disease, coronary artery
bypass grafting, percutaneous coronary intervention, stroke/
transient ischemic attack, abdominal aortic aneurysm, periph-
eral arterial disease, carotid artery stenosis, or noncoronary
arterial revascularization. Patients qualiﬁed for high-intensity
statin therapy for primary prevention if they had the following:
(1) low-density lipoprotein cholesterol ≥190 mg/dL or
(2) diabetes mellitus with a 10-year ASCVD risk ≥7.5%.
Patients qualiﬁed for at least moderate-intensity statin
therapy if they had no indication for high-intensity statin
and one of the following: (1) diabetes mellitus with a 10-year
ASCVD risk <7.5% or (2) 10-year ASCVD risk ≥7.5% on the
basis of the pooled cohort risk equation and no diabetes
mellitus. Because the 10-year risk calculator is meant to be
used for those 40 to 79 years old, we calculated risk for those
≥80 years as if they were 79 years, which represents the
minimum risk for these adults given increased risk with age.
Any statin and high-intensity statin therapy were considered
outcomes of interest. Statin intensity was deﬁned on the basis
of the daily dose at the time of enrollment using the previously
deﬁned 2013 ACC/AHA cholesterol guideline schema.1 High-
intensity statin therapy was deﬁned as atorvastatin ≥40 mg or
rosuvastatin ≥20 mg daily. Covariates included patient demo-
graphics and socioeconomic characteristics, medical history,
laboratory results, patient beliefs about statins, adverse
effects, and willingness for change. Patient surveys were
administered via an iPad before being seen in the clinic. These
surveys included questions on beliefs about statins, adverse
effects, and willingness for change. Symptoms were assessed
in patients ≤75 and >75 years, within subgroups of patients
currently receiving statin therapy or speciﬁcally receiving high-
intensity statin therapy and those previously receiving statin
therapy who had since stopped therapy (Table S1).
Missing data were infrequent, except for the income
variable. For multivariable modeling, missing values of
Clinical Perspective
What Is New?
• Since the release of the 2013 American College of
Cardiology/American Heart Association guideline, older
patients (>75 years old) with atherosclerotic cardiovascular
disease were less likely than their younger counterparts to
receive high-intensity statins.
• Among primary prevention patients, statin use was similar
among older and younger patients.
• Statins were similarly tolerated between older and younger
patients.
What Are the Clinical Implications?
• Treatment differences between high-risk older and younger
patients with atherosclerotic cardiovascular disease may
represent a therapeutic opportunity for improvement and
highlight the importance of future randomized controlled
trials evaluating high-intensity statin use in older adults for
secondary prevention.
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continuous variables were imputed using the median, and
missing values of categorical variables were imputed to the
most common value. Missing/do not know/prefer not to
answer responses for the income variable were imputed to
the 2014 median census household income on the basis of
the patient residence zip code or the enrolling site zip code if
the patient zip code was missing.
Statistical Analysis
Overall and by subgroups, we described patient characteris-
tics of the study population by age group (>75 versus
≤75 years) using frequencies with percentages for categorical
variables and medians with interquartile range for continuous
variables. For categorical variables, we tested for differences
between age groups using v2 tests when the cell number was
≥5 and Fisher’s exact tests when the cell number was <5. We
used Kruskal-Wallis tests for continuous variables.
We then estimated the unadjusted and adjusted associa-
tion between age and outcomes (statin and high-intensity
statin use) using logistic regression models overall and by
subgroups of primary and secondary prevention. In the
unadjusted model, age was the only independent variable.
Prespeciﬁed clinically relevant variables possibly associated
with statin use were included in the multivariable model to
control for potential confounding, and they were retained in
the models regardless of statistical signiﬁcance. In the
adjusted (multivariable) model, independent variables
included age and covariates (sex, race, ASCVD, including
myocardial infarction, coronary artery disease, coronary artery
bypass grafting, percutaneous coronary intervention, stroke/
transient ischemic attack, abdominal aortic aneurysm, periph-
eral arterial disease, carotid artery stenosis, noncoronary
arterial revascularization, diabetes mellitus, heart failure,
chronic kidney disease, smoking, body mass index, insurance
status by type, annual income, and whether the patient saw a
cardiologist). For primary prevention, the models did not
include history of ASCVD. We reported the estimated odds
ratios (ORs) and 95% conﬁdence intervals (CIs). We used a 2-
tailed a=0.05 to establish statistical signiﬁcance of all tests.
All analyses were performed using SAS, version 9.4 (SAS
Institute, Inc, Cary, NC).
Results
A total of 6717 patients (n=3425 with clinical ASCVD) had an
indication for statin therapy, including 1704 (25%) >75 years.
The baseline characteristics of older adults differed from
younger adults in the PALM registry (Table 1). Older patients
were more frequently white than younger adults (88.4% versus
79.5% [P<0.001] in primary prevention; 92.9% versus 84.6%
[P<0.0001] in secondary prevention). Overall, older patients
had higher rates of established ASCVD compared with
younger adults (60.9% versus 47.6%; P<0.0001). Among
those with a history of ASCVD, older adults more frequently
had peripheral artery disease (20.9% versus 17.1%; P=0.008),
coronary artery disease (80.0% versus 75.3%; P=0.003),
carotid stenosis (20.9% versus 17.1%; P=0.008), prior coro-
nary artery bypass grafting (28.3% versus 21.1%; P<0.0001),
and abdominal aortic aneurysm (6.7% versus 3.9%; P<0.001),
but less frequently had a history of myocardial infarction
(25.9% versus 30.9%; P=0.003) or percutaneous coronary
intervention (37.8% versus 42.8%; P=0.006) (Table 1). Com-
pared with younger adults, older patients had a higher
prevalence of heart failure and chronic kidney disease, but a
lower prevalence of diabetes mellitus and a lower body mass
index. Older adults were somewhat more likely to receive
moderate-intensity statin therapy for secondary prevention
(56.6% versus 47.9%; P<0.0001) (Figure 1). Nevertheless, in
secondary prevention settings, older individuals were less
likely to be treated with any statin overall (80.1% versus
84.2%; P=0.003) and much less likely to receive high-intensity
statins (23.5% versus 36.2%; P<0.0001). In multivariable
analyses, there was no difference in statin use or high-
intensity statin use between older and younger adults eligible
for statins for purposes of primary prevention (statin OR, 1.07
[95% CI, 0.88–1.30]; high-intensity statin OR, 0.92 [95% CI,
0.68–1.24]) (Figure 2). Yet, older adults with prior ASCVD had
a trend toward lower ORs of overall statin use (OR, 0.81; 95%
CI, 0.66–1.01; P=0.06) and were less likely to be treated with
a high-intensity statin (OR, 0.54; 95% CI, 0.45–0.65;
P=0.0001).
Patient-reported symptoms while receiving statins, statin
discontinuation rates, and reasons for discontinuation were
analyzed by age group (Table 2). The prevalence of prior statin
discontinuation was similar among older versus younger
adults (11.4% for those >75 versus 9.8% for those ≤75 years;
P=0.09). Adverse effects were also noted as a reason for
stopping at similar rates in older versus younger individuals
(58.0% versus 53.4%; P=0.35). Among adults currently
receiving a statin, older patients were actually less likely to
report experiencing any adverse symptoms (41.3% versus
46.6%; P=0.003) or myalgias speciﬁcally (27.3% versus 33.3%;
P<0.001). These trends were similar among older versus
younger patients who were taking a high-intensity statin.
Discussion
Patients >75 years have been poorly represented in large
primary and secondary ASCVD prevention statin trials. Conse-
quently, the ACC/AHA andmore recent US Preventive Services
Task Force guidelines do not recommend statins for primary
prevention in older adults, although the former allows for risk
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Table 1. Baseline Characteristics by Age (n=6717)
Characteristics
Primary Prevention (n=3292) Secondary Prevention (n=3425)
Aged ≤75 y (n=2626) Aged >75 y (n=666) P Value Aged ≤75 y (n=2387) Aged >75 y (n=1038) P Value
Male sex 1260 (48.0) 275 (41.3) 0.002 1555 (65.1) 611 (58.9) <0.001
Age, y 66.0 (58.0–70.0) 80.0 (77.0–83.0) <0.0001 67.0 (60.0–71.0) 80.5 (78.0–84.0) <0.0001
Race <0.001 <0.0001
White 2088 (79.5) 589 (88.4) 2020 (84.6) 964 (92.9)
Black 476 (18.1) 67 (10.1) 308 (12.9) 57 (5.5)
Other/unknown 62 (2.4) 10 (1.5) 59 (2.5) 17 (1.6)
Hispanic 414 (15.8) 74 (11.1) 0.003 172 (7.2) 71 (6.8) 0.70
10-y risk (among those
without ASCVD*)
14.4 (9.5–22.0) 32.4 (26.2–43.3) <0.0001
Prior MI . . . . . . . . . 738 (30.9) 269 (25.9) 0.003
Prior stroke . . . . . . . . . 232 (9.7) 109 (10.5) 0.48
PAD . . . . . . . . . 408 (17.1) 217 (20.9) 0.008
Coronary artery disease . . . . . . . . . 1798 (75.3) 830 (80.0) 0.003
Prior CABG . . . . . . . . . 504 (21.1) 294 (28.3) <0.0001
Prior PCI . . . . . . . . . 1021 (42.8) 392 (37.8) 0.006
Abdominal aortic aneurysm . . . . . . . . . 93 (3.9) 70 (6.7) <0.001
Carotid artery stenosis . . . . . . . . . 408 (17.1) 217 (20.9) 0.008
History of TIA . . . . . . . . . 165 (6.9) 86 (8.3) 0.16
Prior noncoronary arterial
revascularization
. . . . . . . . . 108 (4.5) 49 (4.7) 0.80
Total cholesterol, mg/dL 181.0 (156.0–212.0) 176.5 (152.0–205.0) 0.002 158.0 (137.0–189.0) 155.0 (134.0–185.0) 0.04
LDL-C, mg/dL 105.0 (83.0–131.0) 99.0 (79.0–123.0) <0.0001 87.0 (68.0–110.0) 83.0 (66.0–107.0) 0.03
LDL-C on treatment, mg/dL 94.0 (75.0–116.0) 89.0 (72.0–107.0) 0.002 82.0 (66.0–102.0) 79.0 (63.0–97.0) 0.001
LDL-C not on treatment, mg/dL 123.0 (100.0–146.0) 118.0 (95.0–140.0) 0.005 114.0 (84.0–143.0) 110.0 (83.0–132.0) 0.17
HDL-C, mg/dL 52.0 (43.0–64.0) 58.0 (47.0–69.0) <0.0001 49.0 (40.0–59.0) 52.0 (44.0–62.0) <0.0001
Diabetes mellitus 1367 (52.1) 185 (27.8) <0.0001 1022 (42.8) 354 (34.1) <0.0001
Hypertension 2008 (76.5) 523 (78.5) 0.26 2008 (84.1) 908 (87.5) 0.01
Heart failure 87 (3.3) 54 (8.1) <0.0001 334 (14.0) 195 (18.8) <0.0001
Chronic kidney disease 180 (6.9) 88 (13.2) <0.0001 267 (11.2) 179 (17.2) <0.0001
BMI, kg/m2 30.7 (27.3–35.6) 27.1 (24.5–31.4) <0.0001 30.3 (26.6–34.8) 27.5 (24.8–31.3) <0.0001
Smoking status <0.0001 <0.0001
Current smoker 304 (12.4) 24 (3.9) 320 (14.1) 33 (3.4)
Quit/former smoker 904 (37.0) 266 (43.0) 1080 (47.6) 529 (54.4)
Never smoked 1236 (50.6) 329 (53.2) 868 (38.3) 411 (42.2)
College or above 1525 (62.9) 344 (56.4) 0.003 1507 (66.7) 540 (55.7) <0.0001
Insurance†
Private 1465 (60.2) 317 (51.5) <0.0001 1377 (57.7) 514 (49.5) <0.0001
Medicare 1305 (53.7) 537 (87.0) <0.0001 1324 (55.5) 854 (82.3) <0.0001
Medicaid 264 (10.9) 68 (11.0) 0.90 287 (12.0) 77 (7.4) <0.0001
No insurance 76 (3.1) 7 (1.1) 0.007 39 (1.6) 8 (0.8) 0.05
Other 59 (2.2) 8 (1.2) 0.09 44 (1.8) 19 (1.8) 0.98
Continued
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discussion, while suggesting less intense therapy for secondary
prevention.1,12 Despite a lack of evidence and ﬁrm treatment
guidelines, clinicians need to make therapeutic decisions about
lipid management in older patients. In our large, contemporary,
practice-based study, we found that many patients >75 years
in primary prevention are receiving a statin. What is unclear is
Table 1. Continued
Characteristics
Primary Prevention (n=3292) Secondary Prevention (n=3425)
Aged ≤75 y (n=2626) Aged >75 y (n=666) P Value Aged ≤75 y (n=2387) Aged >75 y (n=1038) P Value
Income‡ <0.0001 <0.0001
<$35 000 598 (34.9) 147 (43.5) 537 (35.2) 242 (44.6)
$35 000–$75 000 586 (34.1) 115 (34.0) 473 (31.0) 195 (36.0)
$75 000–$100 000 197 (11.5) 38 (11.2) 182 (11.9) 47 (8.7)
≥$100 000 334 (19.5) 38 (11.2) 334 (21.9) 58 (10.7)
Seen by a cardiologist 723 (27.5) 295 (44.3) <0.0001 1861 (78.0) 815 (78.5) 0.72
Seen by an endocrinologist 506 (19.3) 66 (9.9) <0.0001 451 (18.9) 119 (11.5) <0.0001
All values are expressed as median (interquartile range) or number (percentage), where appropriate. ASCVD indicates atherosclerotic cardiovascular disease; BMI, body mass index; CABG,
coronary artery bypass grafting; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; PAD, peripheral artery disease; PCI,
percutaneous coronary intervention; TIA, transient ischemic attack.
*ASCVD includes prior MI, coronary artery disease, CABG, PCI, stroke, abdominal aortic aneurysm, peripheral arterial disease, carotid artery stenosis, noncoronary arterial
revascularization, or prior TIA.
†Insurance: “other” includes all answers that are not “no,” “private,” “Medicare,” or “Medicaid.”
‡Income: excludes “I do not know” and “prefer not to answer” from denominator. Income is based on self-report; when missing, we used zip code–based median income for modeling.
Figure 1. Statin use in older vs younger adults. Primary and secondary prevention statin use in older vs
younger adults, according to those treated with any statin, a high-intensity statin, and a moderate-intensity
statin.
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whether physicians are extrapolating treatment algorithms
used for their younger patients and applying these algorithms
to their older patients, particularly for primary prevention. In the
setting of primary prevention, older and younger patients had a
similar likelihood of receiving statin therapy, including high-
intensity statin therapy. Nonetheless, in secondary prevention,
physicians appeared to follow the ACC/AHA guidelines and
prescribed lower-dose statins in older individuals with ASCVD.
Finally, relative to younger patients, we found that older
individuals treated with any or high-intensity statins speciﬁcally
had similar likelihoods of having adverse symptoms as their
similarly treated younger peers.
Although the absolute risk of cardiovascular disease
increases with advancing age, prior studies have demon-
strated that older adults were less likely to be treated with
statins than their younger counterparts.15,16 Older adults in
the PALM registry represent a high-risk population, with
higher rates of ASCVD than younger patients, and had a
higher prevalence of being treated with statins, particularly
moderate-intensity statins. Older adults in the lower-risk
primary prevention cohort were equally likely to be treated
with any statin or a high-intensity statin for primary preven-
tion. Conversely, higher-risk older adults with a history of
ASCVD were less likely than their younger counterparts to be
treated with statins overall or with high-intensity statin
therapy. The treatment difference in high-intensity statin use
among patients with known ASCVD was particularly striking,
and older patients more frequently received moderate-
intensity statin therapy, which suggests that clinicians have
been applying the most recent ACC/AHA guideline recom-
mendation for moderate-intensity statins to older patients
with an ASCVD history.1 Other factors affecting access to
statins may also affect statin use, such as lower income,
varying insurance coverage, competing illnesses and comor-
bidities, and higher likelihood of being homebound, although
differences in high-intensity statin use persisted even after
correction for heart failure, income, and insurance status.
Differences in type of ASCVD between older and younger
populations may also contribute to differences in statin
treatment patterns, with younger populations more frequently
having a history of myocardial infarction or percutaneous
coronary intervention, which may be more likely to prompt
Figure 2. Adjusted association between age (>75 vs ≤75 years) and statin use. For overall and secondary
prevention, model adjusted for sex, race, atherosclerotic cardiovascular disease (including myocardial
infarction, coronary artery disease, coronary artery bypass grafting, percutaneous coronary intervention,
stroke, abdominal aortic aneurysm, peripheral arterial disease, carotid artery stenosis, noncoronary arterial
revascularization, and prior transient ischemic attack), diabetes mellitus, heart failure, chronic kidney
disease (CKD), smoking, body mass index (BMI), insurance, income, and whether the patient saw a
cardiologist. For primary prevention, model adjusted for sex, race, diabetes mellitus, heart failure, CKD,
smoking, BMI, insurance, income, and whether the patient saw a cardiologist. CI indicates conﬁdence
interval.
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high-intensity statin use than other forms of ASCVD. Among
very old patients, limited life expectancy may lead to joint
decisions between the patient and provider to lower statin
intensity or discontinue therapy entirely.
Despite their high risk of ASCVD, the evidence for primary
prevention statin therapy and high-intensity statin therapy in
secondary prevention in older adults is incomplete.4,5,17,18
Clinical trial data suggest a clinical beneﬁt of moderate-
intensity statins in those aged ≥75 years when used for
secondary prevention, and prior observational studies have
demonstrated a signiﬁcant risk reduction gleaned from statin
therapy in this population.11,15,16,19 Similarly, a recent obser-
vational study suggests a signiﬁcant survival advantage exists
among older adults with ASCVD treated with high- versus
moderate-intensity statins, ampliﬁed at maximal doses of high-
intensity statins.20 On the other hand, a recent post hoc
analysis from the ALLHAT-LLT (Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial) found a
signal (P=0.07) for possible increased all-cause mortality
among older adults treated with statins.7 These ﬁndings
highlight the necessity for clinical trials to evaluate the efﬁcacy
and safety of statin therapy, including high-intensity therapy,
for both primary and secondary prevention of cardiovascular
disease, speciﬁcally in older adults. One such example is the
ongoing STAREE (Statin Therapy for Reducing Events in the
Elderly) trial (NCT02099123). This trial is randomizing older
adults (≥70 years) without prior ASCVD to high-intensity statin
therapy with atorvastatin 80 mg or placebo, and it features
several relevant geriatric end points, including measures of
cognitive function, disability, frailty, and quality of life.
Although some cite adverse effect risk as a potential cause
for statin underuse in older populations, we observed similar
Table 2. Statin Experience and Willingness to Try a Cholesterol-Lowering Medication Among Those Previously Not Receiving a
Statin
Variable Those Aged ≤75 y Those Aged >75 y P Value*
Among those currently receiving a statin (n=4641)
Experienced any symptoms 1519 (46.6) 446 (41.3) 0.003
Experienced myalgias 1083 (33.3) 294 (27.3) <0.001
Among those currently receiving a high-intensity statin (n=1358)
Experienced any symptoms 493 (48.2) 89 (35.3) <0.001
Experienced myalgias 352 (34.5) 49 (19.5) <0.0001
Among those previously receiving a statin (n=525)
Reason for stopping
No longer needed 68 (18.6) 27 (18.9) 0.95
Did not like taking daily 23 (6.3) 3 (2.1) 0.07
Cost/expense or lost/changed insurance 30 (8.2) 6 (4.2) 0.11
Did not notice improvement 18 (4.9) 3 (2.1) 0.21
Prefer natural remedies 28 (7.7) 7 (4.9) 0.27
Adverse effects 195 (53.4) 83 (58.0) 0.35
Friend/relative/other information suggested stopping 22 (6.0) 6 (4.2) 0.42
Do not know/cannot remember 38 (10.4) 15 (10.5) 0.98
Among those who were never receiving a statin (n=1551)
Ever recommended (% yes) 137 (18.8) 45 (18.2) 0.83
Willingness to try a cholesterol-lowering medication
Not at all or unlikely 89 (16.7) 38 (20.4) 0.02
Possibly 173 (32.5) 46 (24.7)
Very likely or almost certainly 233 (43.8) 78 (41.9)
Do not know 37 (7.0) 24 (12.9)
Data are presented as number (percentage), with the percentage generated as a percentage of the number of patients in that particular age (≤75 vs >75 years old) and statin treatment
status subgroup (currently receiving a statin, currently receiving a high-intensity statin, previously receiving a statin, or never receiving a statin). All percentages were calculated as a
percentage of nonmissing.
*v2 Tests were used when the cell number was ≥5. Fisher’s exact tests were used when the cell number was <5.
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rates of reported statin symptoms in older versus younger
patients. In fact, older adults currently receiving statins were
less likely to report symptoms than younger adults. These
ﬁndings are signiﬁcant, particularly given the perceived
increased risk of statin adverse effects in older adults that
is prevalent in the literature, despite prior studies suggesting
otherwise1,6,21–24; whether providers hold similar beliefs
about statins deserves further exploration.
This study captures a large number of outpatient older adults
from 138 different sites, representing a highly generalizable
cohort that is likely representative of the larger US population.
In addition, this is the ﬁrst study to characterize statin
treatment patterns among older adults since the release of
the 2013 ACC/AHA guideline, as well as the ﬁrst study to
capture patient-related perceptions and beliefs about statins
(both of which are important contributions to cardiology and
geriatrics literature). Despite these strengths, our study had
some limitations. First, we were unable to capture speciﬁc
clinician perceptions and beliefs that may have inﬂuenced
treatment patterns; this information would have provided a
more comprehensive understanding of the forces inﬂuencing
statin use in older adults. Second, recall bias may affect the
ability of older individuals to remember an adverse effect,
because of age-related cognitive changes. Third, individuals
currently receiving a statin are less likely to have had a prior
adverse effect, which may lead to selection bias. Fourth, it was
impossible to determine whether symptoms described by
patients were directly attributable to statin therapy, and it is
unlikely that reported symptoms were all directly attributed to
statin use. Fifth, for the primary prevention subgroup, we
estimated ASCVD risk with the pooled cohort equation, which is
meant for use in patients 40 to 79 years old. As a result, this
method may not have accurately estimated ASCVD risk in
patients ≥80 years old. Sixth, we did not collect information on
the timing of initiation or duration of statin therapy. Finally, we
did not capture detailed information on geriatric impairments
and frailty that may play a role in therapeutic decision making in
the older adult population.
In conclusion, older and younger patients in the PALM
registry were similarly likely to receive statins for primary
prevention; however, older individuals less frequently received
statin therapy and, in particular, high-intensity statin therapy
for secondary prevention. Statins were similarly tolerated in
older and younger adults. Future clinical trials are needed to
more deﬁnitively identify the proper statin treatment
approach in older patients.
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Table S1. Adverse Symptom Example Survey Questions. 
 
Example side effect and symptom related questions from the PALM patient survey.  
 
Have you experienced any of the following symptoms while taking a statin?  
Please select all that apply. 
If currently or previously on a statin 
    [ ] muscle aches/cramps 
    [ ] memory loss, forgetfulness, or confusion 
    [ ] weakness 
    [ ] nausea/vomiting/stomach upset 
    [ ] constipation 
    [ ] fatigue 
    [ ] hives/itching 
    [ ] other (free text) 
    [ ] I have not experienced any symptoms 
    [ ] I don’t know/can’t remember 
What was the reason for stopping your last statin? Please select all that apply. 
If not on a statin now, but previously on a statin 
    [ ] My doctor felt it was no longer needed 
    [ ] I didn’t like taking a medication every day 
    [ ] Too expensive/cost 
    [ ] I lost/changed my insurance 
    [ ] I did not notice any improvement in how I felt while on this medication 
    [ ] I prefer natural remedies or supplements instead of prescription medicines 
    [ ] I had side effects 
    [ ] A friend or relative recommended I stop 
    [ ] Information I read (online, magazine) or heard suggested that I stop 
    [ ] Other ____ 
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